ID   KALRN_RAT               Reviewed;        2959 AA.
AC   P97924; O70135; Q6IV51; Q9JIF1; Q9JIF2; Q9JIG0; Q9JIH3;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   23-OCT-2007, sequence version 3.
DT   02-OCT-2024, entry version 204.
DE   RecName: Full=Kalirin {ECO:0000303|PubMed:9139723};
DE            EC=2.7.11.1;
DE   AltName: Full=Huntingtin-associated protein-interacting protein;
DE   AltName: Full=PAM COOH-terminal interactor protein 10;
DE            Short=P-CIP10;
DE   AltName: Full=Protein Duo;
DE   AltName: Full=Serine/threonine-protein kinase with Dbl- and pleckstrin homology domain;
GN   Name=Kalrn {ECO:0000312|RGD:621865}; Synonyms=Duo, Hapip;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Hippocampus;
RX   PubMed=8910496; DOI=10.1074/jbc.271.45.28636;
RA   Alam M.R., Caldwell B.D., Johnson R.C., Darlington D.N., Mains R.E.,
RA   Eipper B.A.;
RT   "Novel proteins that interact with the COOH-terminal cytosolic routing
RT   determinants of an integral membrane peptide-processing enzyme.";
RL   J. Biol. Chem. 271:28636-28640(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2 AND 3), AND INTERACTION WITH PAM.
RC   TISSUE=Hippocampus;
RX   PubMed=9139723; DOI=10.1074/jbc.272.19.12667;
RA   Alam M.R., Johnson R.C., Darlington D.N., Hand T.A., Mains R.E.,
RA   Eipper B.A.;
RT   "Kalirin, a cytosolic protein with spectrin-like and GDP/GTP exchange
RT   factor-like domains that interacts with peptidylglycine alpha-amidating
RT   monooxygenase, an integral membrane peptide-processing enzyme.";
RL   J. Biol. Chem. 272:12667-12675(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 6), FUNCTION, SUBCELLULAR LOCATION, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=10692441; DOI=10.1074/jbc.275.9.6395;
RA   Penzes P., Johnson R.C., Alam M.R., Kambampati V., Mains R.E., Eipper B.A.;
RT   "An isoform of kalirin, a brain-specific GDP/GTP exchange factor, is
RT   enriched in the postsynaptic density fraction.";
RL   J. Biol. Chem. 275:6395-6403(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 5 AND 7), ALTERNATIVE INITIATION,
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=10777487; DOI=10.1074/jbc.m000676200;
RA   Johnson R.C., Penzes P., Eipper B.A., Mains R.E.;
RT   "Isoforms of kalirin, a neuronal Dbl family member, generated through use
RT   of different 5'- and 3'-ends along with an internal translational
RT   initiation site.";
RL   J. Biol. Chem. 275:19324-19333(2000).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 8), AND FUNCTION.
RX   PubMed=15950621; DOI=10.1016/j.yexcr.2005.03.024;
RA   Schiller M.R., Blangy A., Huang J., Mains R.E., Eipper B.A.;
RT   "Induction of lamellipodia by Kalirin does not require its guanine
RT   nucleotide exchange factor activity.";
RL   Exp. Cell Res. 307:402-417(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 638-1216 (ISOFORM 4).
RC   TISSUE=Brain cortex, and Hippocampus;
RX   PubMed=9285789; DOI=10.1093/hmg/6.9.1519;
RA   Colomer V., Engelender S., Sharp A.H., Duan K., Cooper J.K., Lanahan A.,
RA   Lyford G., Worley P., Ross C.A.;
RT   "Huntingtin-associated protein 1 (HAP1) binds to a Trio-like polypeptide,
RT   with a rac1 guanine nucleotide exchange factor domain.";
RL   Hum. Mol. Genet. 6:1519-1525(1997).
RN   [7]
RP   FUNCTION, DOMAIN, AND DEVELOPMENTAL STAGE.
RX   PubMed=11606631; DOI=10.1523/jneurosci.21-21-08426.2001;
RA   Penzes P., Johnson R.C., Kambampati V., Mains R.E., Eipper B.A.;
RT   "Distinct roles for the two Rho GDP/GTP exchange factor domains of kalirin
RT   in regulation of neurite growth and neuronal morphology.";
RL   J. Neurosci. 21:8426-8434(2001).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1772; THR-1785 AND SER-1790,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
RN   [9]
RP   STRUCTURE BY NMR OF 1617-1707, DOMAIN, AND INTERACTION WITH CRK1.
RX   PubMed=16644733; DOI=10.1074/jbc.m512482200;
RA   Schiller M.R., Chakrabarti K., King G.F., Schiller N.I., Eipper B.A.,
RA   Maciejewski M.W.;
RT   "Regulation of RhoGEF activity by intramolecular and intermolecular SH3
RT   domain interactions.";
RL   J. Biol. Chem. 281:18774-18786(2006).
CC   -!- FUNCTION: Promotes the exchange of GDP by GTP. Activates specific Rho
CC       GTPase family members, thereby inducing various signaling mechanisms
CC       that regulate neuronal shape, growth, and plasticity, through their
CC       effects on the actin cytoskeleton. Induces lamellipodia independent of
CC       its GEF activity. Isoforms 1 and 7 are necessary for neuronal
CC       development and axonal outgrowth. Isoform 6 is required for dendritic
CC       spine formation. {ECO:0000269|PubMed:10692441,
CC       ECO:0000269|PubMed:11606631, ECO:0000269|PubMed:15950621}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1;
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC   -!- SUBUNIT: Interacts with the C-terminal of peptidylglycine alpha-
CC       amidating monooxygenase (PAM) and with the huntingtin-associated
CC       protein 1 (HAP1). Interacts with FASLG (By similarity). {ECO:0000250}.
CC   -!- INTERACTION:
CC       P97924; P54256: Hap1; NbExp=3; IntAct=EBI-1397166, EBI-994539;
CC       P97924-5; Q62765: Nlgn1; NbExp=5; IntAct=EBI-26961214, EBI-7281118;
CC       P97924-5; Q99K10: Nlgn1; Xeno; NbExp=2; IntAct=EBI-26961214, EBI-775037;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Cytoplasm, cytoskeleton. Note=Isoform
CC       6 is largely associated with synaptosomal membranes and to punctate
CC       structures in cortical neurons. Isoforms 1 and 7 are expressed in
CC       neuronal cell bodies, isoform 7 is also found in neuronal processes.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing, Alternative initiation; Named isoforms=8;
CC       Name=1; Synonyms=Kalirin-12A;
CC         IsoId=P97924-1; Sequence=Displayed;
CC       Name=2; Synonyms=Kalirin-8B, P-CIP10B;
CC         IsoId=P97924-2; Sequence=VSP_028891, VSP_028899, VSP_028900;
CC       Name=3; Synonyms=Kalirin-8A, P-CIP10A;
CC         IsoId=P97924-3; Sequence=VSP_028899, VSP_028900;
CC       Name=4;
CC         IsoId=P97924-4; Sequence=VSP_028896;
CC       Name=5; Synonyms=Delta Kalirin-7;
CC         IsoId=P97924-5; Sequence=VSP_028893, VSP_028897, VSP_028898;
CC       Name=6; Synonyms=Kalirin-7, Kalirin-7c, HAPIP;
CC         IsoId=P97924-6; Sequence=VSP_028892, VSP_028897, VSP_028898;
CC       Name=7; Synonyms=Kalirin-9A;
CC         IsoId=P97924-7; Sequence=VSP_028901, VSP_028902;
CC       Name=8; Synonyms=Kalirin-4a;
CC         IsoId=P97924-8; Sequence=VSP_028894, VSP_028895;
CC   -!- TISSUE SPECIFICITY: Highly expressed in the brain and nervous system.
CC       Isoform 6 is highly enriched in the postsynaptic density fraction of
CC       the cerebral cortex. {ECO:0000269|PubMed:10692441,
CC       ECO:0000269|PubMed:10777487}.
CC   -!- DEVELOPMENTAL STAGE: Isoforms 1 and 7 are prevelant 2 dpp, isoform 6 is
CC       not detectable until 2 weeks after birth.
CC       {ECO:0000269|PubMed:11606631}.
CC   -!- DOMAIN: The two GEF domains catalyze nucleotide exchange for RAC1 and
CC       RhoA which are bound by DH1 and DH2 respectively. The two GEF domains
CC       appear to play differing roles in neuronal development and axonal
CC       outgrowth. SH3 1 binds to the first GEF domain inhibiting GEF activity
CC       only when in the presence of a PXXP peptide, suggesting that the SH3
CC       domain/peptide interaction mediates binding to GEF1. CRK1 SH3 domain
CC       binds to and inhibits GEF1 activity. {ECO:0000269|PubMed:11606631,
CC       ECO:0000269|PubMed:16644733}.
CC   -!- PTM: Autophosphorylated. {ECO:0000250}.
CC   -!- MISCELLANEOUS: Called DUO because the encoded protein is closely
CC       related to but shorter than TRIO.
CC   -!- MISCELLANEOUS: [Isoform 1]: Produced by alternative splicing.
CC   -!- MISCELLANEOUS: [Isoform 2]: Produced by alternative splicing.
CC       {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 3]: Produced by alternative splicing.
CC       {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 4]: Produced by alternative splicing.
CC       {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 5]: Produced by alternative initiation at Met-
CC       624 of isoform 6. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 6]: Produced by alternative splicing.
CC       {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 7]: Produced by alternative splicing.
CC       {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 8]: Produced by alternative splicing.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr
CC       protein kinase family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U88156; AAB66366.1; -; mRNA.
DR   EMBL; U88157; AAB66367.1; -; mRNA.
DR   EMBL; AF230644; AAF69144.1; -; mRNA.
DR   EMBL; AF229255; AAF66014.1; -; mRNA.
DR   EMBL; AF232668; AAF66018.1; -; mRNA.
DR   EMBL; AF232669; AAF66019.1; -; mRNA.
DR   EMBL; AY621095; AAT39517.1; -; mRNA.
DR   EMBL; U94189; AAC15790.1; -; mRNA.
DR   PIR; T32732; T32732.
DR   PIR; T42098; T42098.
DR   RefSeq; NP_114451.2; NM_032062.2.
DR   PDB; 1U3O; NMR; -; A=1617-1686.
DR   PDB; 2KR9; NMR; -; A=1253-1432.
DR   PDB; 5O33; X-ray; 1.64 A; B=1253-1432.
DR   PDBsum; 1U3O; -.
DR   PDBsum; 2KR9; -.
DR   PDBsum; 5O33; -.
DR   SMR; P97924; -.
DR   BioGRID; 249875; 7.
DR   CORUM; P97924; -.
DR   IntAct; P97924; 17.
DR   MINT; P97924; -.
DR   STRING; 10116.ENSRNOP00000039072; -.
DR   ChEMBL; CHEMBL2176786; -.
DR   iPTMnet; P97924; -.
DR   PhosphoSitePlus; P97924; -.
DR   PaxDb; 10116-ENSRNOP00000039072; -.
DR   DNASU; 84009; -.
DR   GeneID; 84009; -.
DR   KEGG; rno:84009; -.
DR   UCSC; RGD:621865; rat. [P97924-1]
DR   AGR; RGD:621865; -.
DR   CTD; 8997; -.
DR   RGD; 621865; Kalrn.
DR   VEuPathDB; HostDB:ENSRNOG00000001706; -.
DR   eggNOG; KOG0032; Eukaryota.
DR   eggNOG; KOG0613; Eukaryota.
DR   eggNOG; KOG4240; Eukaryota.
DR   InParanoid; P97924; -.
DR   OrthoDB; 2906033at2759; -.
DR   PhylomeDB; P97924; -.
DR   Reactome; R-RNO-193648; NRAGE signals death through JNK.
DR   Reactome; R-RNO-3928662; EPHB-mediated forward signaling.
DR   Reactome; R-RNO-416476; G alpha (q) signalling events.
DR   Reactome; R-RNO-416482; G alpha (12/13) signalling events.
DR   Reactome; R-RNO-5687128; MAPK6/MAPK4 signaling.
DR   Reactome; R-RNO-8980692; RHOA GTPase cycle.
DR   Reactome; R-RNO-9013149; RAC1 GTPase cycle.
DR   Reactome; R-RNO-9013408; RHOG GTPase cycle.
DR   EvolutionaryTrace; P97924; -.
DR   PRO; PR:P97924; -.
DR   Proteomes; UP000002494; Chromosome 11.
DR   Bgee; ENSRNOG00000001706; Expressed in frontal cortex and 20 other cell types or tissues.
DR   ExpressionAtlas; P97924; baseline and differential.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005856; C:cytoskeleton; IEA:UniProtKB-SubCell.
DR   GO; GO:0019898; C:extrinsic component of membrane; IBA:GO_Central.
DR   GO; GO:0098978; C:glutamatergic synapse; IDA:SynGO.
DR   GO; GO:0043025; C:neuronal cell body; IDA:RGD.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:RGD.
DR   GO; GO:0014069; C:postsynaptic density; IDA:SynGO.
DR   GO; GO:0098793; C:presynapse; IDA:SynGO.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0019899; F:enzyme binding; IPI:RGD.
DR   GO; GO:0005085; F:guanyl-nucleotide exchange factor activity; ISO:RGD.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0008344; P:adult locomotory behavior; ISO:RGD.
DR   GO; GO:0007411; P:axon guidance; IBA:GO_Central.
DR   GO; GO:0007409; P:axonogenesis; IDA:RGD.
DR   GO; GO:0046959; P:habituation; ISO:RGD.
DR   GO; GO:0035556; P:intracellular signal transduction; IDA:HGNC-UCL.
DR   GO; GO:0007595; P:lactation; ISO:RGD.
DR   GO; GO:0042711; P:maternal behavior; ISO:RGD.
DR   GO; GO:0060137; P:maternal process involved in parturition; ISO:RGD.
DR   GO; GO:0007613; P:memory; ISO:RGD.
DR   GO; GO:0098885; P:modification of postsynaptic actin cytoskeleton; IMP:SynGO.
DR   GO; GO:0060125; P:negative regulation of growth hormone secretion; ISO:RGD.
DR   GO; GO:0007399; P:nervous system development; IDA:HGNC-UCL.
DR   GO; GO:0007528; P:neuromuscular junction development; ISO:RGD.
DR   GO; GO:0099645; P:neurotransmitter receptor localization to postsynaptic specialization membrane; IMP:SynGO.
DR   GO; GO:0098989; P:NMDA selective glutamate receptor signaling pathway; IMP:SynGO.
DR   GO; GO:0061003; P:positive regulation of dendritic spine morphogenesis; ISO:RGD.
DR   GO; GO:0050773; P:regulation of dendrite development; IDA:RGD.
DR   GO; GO:1905274; P:regulation of modification of postsynaptic actin cytoskeleton; IDA:SynGO.
DR   GO; GO:0098696; P:regulation of neurotransmitter receptor localization to postsynaptic specialization membrane; IDA:SynGO.
DR   GO; GO:0035176; P:social behavior; ISO:RGD.
DR   CDD; cd00063; FN3; 1.
DR   CDD; cd13240; PH1_Kalirin_Trio_like; 1.
DR   CDD; cd13241; PH2_Kalirin_Trio_p63RhoGEF; 1.
DR   CDD; cd00160; RhoGEF; 2.
DR   CDD; cd00170; SEC14; 1.
DR   CDD; cd11852; SH3_Kalirin_1; 1.
DR   CDD; cd11853; SH3_Kalirin_2; 1.
DR   CDD; cd00176; SPEC; 5.
DR   CDD; cd14115; STKc_Kalirin_C; 1.
DR   Gene3D; 1.20.58.60; -; 5.
DR   Gene3D; 3.40.525.10; CRAL-TRIO lipid binding domain; 1.
DR   Gene3D; 1.20.900.10; Dbl homology (DH) domain; 2.
DR   Gene3D; 2.60.40.10; Immunoglobulins; 2.
DR   Gene3D; 2.30.29.30; Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB); 2.
DR   Gene3D; 2.30.30.40; SH3 Domains; 2.
DR   Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1.
DR   InterPro; IPR001251; CRAL-TRIO_dom.
DR   InterPro; IPR036865; CRAL-TRIO_dom_sf.
DR   InterPro; IPR035899; DBL_dom_sf.
DR   InterPro; IPR000219; DH-domain.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR036116; FN3_sf.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR036179; Ig-like_dom_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR047054; Kalirin_TRIO_PH_1.
DR   InterPro; IPR028570; Kalirin_TRIO_SH3_1.
DR   InterPro; IPR047053; Kalirin_TRIO_SH3_2.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR051336; RhoGEF_Guanine_NuclExch_SF.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR036028; SH3-like_dom_sf.
DR   InterPro; IPR001452; SH3_domain.
DR   InterPro; IPR018159; Spectrin/alpha-actinin.
DR   InterPro; IPR002017; Spectrin_repeat.
DR   PANTHER; PTHR22826:SF49; KALIRIN; 1.
DR   PANTHER; PTHR22826; RHO GUANINE EXCHANGE FACTOR-RELATED; 1.
DR   Pfam; PF13716; CRAL_TRIO_2; 1.
DR   Pfam; PF00041; fn3; 1.
DR   Pfam; PF07679; I-set; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00621; RhoGEF; 2.
DR   Pfam; PF16609; SH3-RhoG_link; 1.
DR   Pfam; PF00018; SH3_1; 1.
DR   Pfam; PF22697; SOS1_NGEF_PH; 2.
DR   Pfam; PF00435; Spectrin; 4.
DR   SMART; SM00060; FN3; 1.
DR   SMART; SM00409; IG; 1.
DR   SMART; SM00408; IGc2; 1.
DR   SMART; SM00233; PH; 2.
DR   SMART; SM00325; RhoGEF; 2.
DR   SMART; SM00220; S_TKc; 1.
DR   SMART; SM00516; SEC14; 1.
DR   SMART; SM00326; SH3; 2.
DR   SMART; SM00150; SPEC; 7.
DR   SUPFAM; SSF52087; CRAL/TRIO domain; 1.
DR   SUPFAM; SSF48065; DBL homology domain (DH-domain); 2.
DR   SUPFAM; SSF49265; Fibronectin type III; 1.
DR   SUPFAM; SSF48726; Immunoglobulin; 1.
DR   SUPFAM; SSF50729; PH domain-like; 2.
DR   SUPFAM; SSF56112; Protein kinase-like (PK-like); 1.
DR   SUPFAM; SSF50044; SH3-domain; 2.
DR   SUPFAM; SSF46966; Spectrin repeat; 6.
DR   PROSITE; PS50191; CRAL_TRIO; 1.
DR   PROSITE; PS50010; DH_2; 2.
DR   PROSITE; PS50853; FN3; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS50002; SH3; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative initiation; Alternative splicing; ATP-binding;
KW   Cytoplasm; Cytoskeleton; Disulfide bond;
KW   Guanine-nucleotide releasing factor; Immunoglobulin domain; Kinase;
KW   Magnesium; Metal-binding; Nucleotide-binding; Phosphoprotein;
KW   Reference proteome; Repeat; Serine/threonine-protein kinase; SH3 domain;
KW   Transferase.
FT   CHAIN           1..2959
FT                   /note="Kalirin"
FT                   /id="PRO_0000080956"
FT   DOMAIN          17..162
FT                   /note="CRAL-TRIO"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00056"
FT   REPEAT          149..290
FT                   /note="Spectrin 1"
FT                   /evidence="ECO:0000255"
FT   REPEAT          292..399
FT                   /note="Spectrin 2"
FT                   /evidence="ECO:0000255"
FT   REPEAT          400..517
FT                   /note="Spectrin 3"
FT                   /evidence="ECO:0000255"
FT   REPEAT          518..621
FT                   /note="Spectrin 4"
FT                   /evidence="ECO:0000255"
FT   REPEAT          622..752
FT                   /note="Spectrin 5"
FT                   /evidence="ECO:0000255"
FT   REPEAT          753..870
FT                   /note="Spectrin 6"
FT                   /evidence="ECO:0000255"
FT   REPEAT          871..977
FT                   /note="Spectrin 7"
FT                   /evidence="ECO:0000255"
FT   REPEAT          978..1101
FT                   /note="Spectrin 8"
FT                   /evidence="ECO:0000255"
FT   REPEAT          1102..1207
FT                   /note="Spectrin 9"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          1254..1429
FT                   /note="DH 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00062"
FT   DOMAIN          1441..1553
FT                   /note="PH 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00145"
FT   DOMAIN          1619..1684
FT                   /note="SH3 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00192"
FT   DOMAIN          1901..2076
FT                   /note="DH 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00062"
FT   DOMAIN          2088..2198
FT                   /note="PH 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00145"
FT   DOMAIN          2293..2358
FT                   /note="SH3 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00192"
FT   DOMAIN          2444..2537
FT                   /note="Ig-like C2-type"
FT   DOMAIN          2544..2638
FT                   /note="Fibronectin type-III"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          2657..2911
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          692..719
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1568..1615
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1703..1828
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2216..2280
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2385..2427
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        703..719
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1590..1615
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1703..1746
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1755..1777
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1786..1810
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        2258..2272
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        2385..2407
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        2776
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         2663..2671
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         2686
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         1723
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O60229"
FT   MOD_RES         1726
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O60229"
FT   MOD_RES         1772
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         1785
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         1790
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         1885
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:A2CG49"
FT   MOD_RES         2234
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O60229"
FT   DISULFID        2465..2521
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   VAR_SEQ         1..623
FT                   /note="Missing (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:10777487"
FT                   /id="VSP_028893"
FT   VAR_SEQ         1..4
FT                   /note="MVLS -> MNPPEGASEEGGAADSDVDAFFRT (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:8910496,
FT                   ECO:0000303|PubMed:9139723"
FT                   /id="VSP_028891"
FT   VAR_SEQ         1..4
FT                   /note="MVLS -> MTDRFWDQWYLWYLRLLRLLDR (in isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:10692441"
FT                   /id="VSP_028892"
FT   VAR_SEQ         705..718
FT                   /note="DSAVSNNKTPHSSS -> SAWAVIPVGNASG (in isoform 8)"
FT                   /evidence="ECO:0000303|PubMed:15950621"
FT                   /id="VSP_028894"
FT   VAR_SEQ         719..2959
FT                   /note="Missing (in isoform 8)"
FT                   /evidence="ECO:0000303|PubMed:15950621"
FT                   /id="VSP_028895"
FT   VAR_SEQ         923
FT                   /note="E -> ESLFHATSLQ (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:9285789"
FT                   /id="VSP_028896"
FT   VAR_SEQ         1617..1636
FT                   /note="LSGGCELTVVLQDFSAAHSS -> DGNLVPRWHLGPGDPFSTYV (in
FT                   isoform 5 and isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:10692441,
FT                   ECO:0000303|PubMed:10777487"
FT                   /id="VSP_028897"
FT   VAR_SEQ         1637..2959
FT                   /note="Missing (in isoform 5 and isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:10692441,
FT                   ECO:0000303|PubMed:10777487"
FT                   /id="VSP_028898"
FT   VAR_SEQ         1860..1899
FT                   /note="TLEGGSYRGSLKDPTVCLNEGMAPPTPPRNLEEEQKAKAL -> VSGHAGGS
FT                   RVLPLTSMWLPGPQLGPQISYLHPDFVYSNCI (in isoform 2 and isoform
FT                   3)"
FT                   /evidence="ECO:0000303|PubMed:8910496,
FT                   ECO:0000303|PubMed:9139723"
FT                   /id="VSP_028899"
FT   VAR_SEQ         1900..2959
FT                   /note="Missing (in isoform 2 and isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:8910496,
FT                   ECO:0000303|PubMed:9139723"
FT                   /id="VSP_028900"
FT   VAR_SEQ         2372..2376
FT                   /note="KSCSW -> TLLKP (in isoform 7)"
FT                   /evidence="ECO:0000303|PubMed:10777487"
FT                   /id="VSP_028901"
FT   VAR_SEQ         2377..2959
FT                   /note="Missing (in isoform 7)"
FT                   /evidence="ECO:0000303|PubMed:10777487"
FT                   /id="VSP_028902"
FT   CONFLICT        46
FT                   /note="T -> S (in Ref. 5; AAT39517)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        62
FT                   /note="N -> Y (in Ref. 5; AAT39517)"
FT                   /evidence="ECO:0000305"
FT   HELIX           1254..1278
FT                   /evidence="ECO:0007829|PDB:5O33"
FT   HELIX           1280..1286
FT                   /evidence="ECO:0007829|PDB:5O33"
FT   STRAND          1287..1289
FT                   /evidence="ECO:0007829|PDB:5O33"
FT   TURN            1293..1297
FT                   /evidence="ECO:0007829|PDB:5O33"
FT   HELIX           1299..1303
FT                   /evidence="ECO:0007829|PDB:5O33"
FT   HELIX           1306..1315
FT                   /evidence="ECO:0007829|PDB:5O33"
FT   HELIX           1317..1323
FT                   /evidence="ECO:0007829|PDB:5O33"
FT   TURN            1324..1326
FT                   /evidence="ECO:0007829|PDB:5O33"
FT   HELIX           1328..1331
FT                   /evidence="ECO:0007829|PDB:5O33"
FT   HELIX           1332..1337
FT                   /evidence="ECO:0007829|PDB:5O33"
FT   HELIX           1339..1343
FT                   /evidence="ECO:0007829|PDB:5O33"
FT   HELIX           1344..1362
FT                   /evidence="ECO:0007829|PDB:5O33"
FT   HELIX           1366..1374
FT                   /evidence="ECO:0007829|PDB:5O33"
FT   HELIX           1380..1384
FT                   /evidence="ECO:0007829|PDB:5O33"
FT   HELIX           1386..1391
FT                   /evidence="ECO:0007829|PDB:5O33"
FT   HELIX           1394..1402
FT                   /evidence="ECO:0007829|PDB:5O33"
FT   HELIX           1409..1428
FT                   /evidence="ECO:0007829|PDB:5O33"
FT   STRAND          1622..1625
FT                   /evidence="ECO:0007829|PDB:1U3O"
FT   STRAND          1645..1650
FT                   /evidence="ECO:0007829|PDB:1U3O"
FT   STRAND          1658..1668
FT                   /evidence="ECO:0007829|PDB:1U3O"
FT   STRAND          1670..1675
FT                   /evidence="ECO:0007829|PDB:1U3O"
FT   HELIX           1676..1678
FT                   /evidence="ECO:0007829|PDB:1U3O"
SQ   SEQUENCE   2959 AA;  336587 MW;  1A3C6770D1CBCC1F CRC64;
     MVLSGSFRND GLKASDVLPI LKEKVAFVSG GRDKRGGPIL TFPARTNHDR IRQEDLRKLV
     TNLASVPSED VCKRGFTVII DMRGSKWDLI KPLLKTLQEA FPAEIHVALI IKPDNFWQKQ
     KTNFGSSKFI FETSMVSVEG LTKLVDPSQL TEEFDGSLDY NHEEWIELRL SLEEFFNSAV
     HLLSRLEDLQ EMLARKEFPV DVEGSRRLID EHTQLKKKVL KAPVEELDRE GQRLLQCIRC
     SDGFSGRNCI PGSADFQSLV PKITSLLDKL HSTRQHLHQM WHVRKLKLDQ CFQLRLFEQD
     AEKMFDWISH NKELFLQSHT EIGVSYQHAL DLQTQHNHFA MNSMNAYVNI NRIMSVASRL
     SEAGHYASQQ IKQISTQLDQ EWKSFAAALD ERSTILAMSA VFHQKAEQFL SGVDAWCKMC
     SEGGLPSEMQ DLELAIHHHQ SLYEQVTQAY TEVSQDGKAL LDVLQRPLSP GNSESLTATA
     NYSKAVHQVL DVVHEVLHHQ RRLESIWQHR KVRLHQRLQL CVFQQDVQQV LDWIENHGEA
     FLSKHTGVGK SLHRARALQK RHDDFEEVAQ NTYTNADKLL EAAEQLAQTG ECDPEEIYKA
     ARHLEVRIQD FVRRVEQRKL LLDMSVSFHT HTKELWTWME DLQKEVLEDV CADSVDAVQE
     LIKQFQQQQT ATLDATLNVI KEGEDLIQQL RSAPPSLGEP TEARDSAVSN NKTPHSSSIS
     HIESVLQQLD DAQVQMEELF HERKIKLDIF LQLRIFEQYT IEVTAELDAW NEDLLRQMND
     FNTEDLTLAE QRLQRHTERK LAMNNMTFEV IQQGQDLHQY IMEVQASGIE LICEKDVDLA
     AQVQELLEFL HEKQHELELN AEQTHKRLEQ CLQLRHLQAE VKQVLGWIRN GESMLNASLV
     NASSLSEAEQ LQREHEQFQL AIEKTHQSAL QVQQKAEALL QAGHYDADAI RECAEKVALH
     WQQLMLKMED RLKLVNASVA FYKTSEQVCS VLESLEQEYR RDEDWCGGRD KLGPAAEMDH
     VIPLLSKHLE QKEAFLKACT LARRNAEVFL KYIHRNNVSM PSVASHTRGP EQQVKAILSE
     LLQRENRVLH FWTLKKRRLD QCQQYVVFER SAKQALDWIQ ETGEYYLSTH TSTGETTEET
     QELLKEYGEF RVPAKQTKEK VKLLIQLADS FVEKGHIHAT EIRKWVTTVD KHYRDFSLRM
     GKYRYTLEKA LGVNTEDNKD LELDIIPASL SDREVKLRDA NHEVNEEKRK SARKKEFIMA
     ELLQTEKAYV RDLHECLETY LWEMTSGVEE IPPGILNKEH IIFGNIQEIY DFHNNIFLKE
     LEKYEQLPED VGHCFVTWAD KFQMYVTYCK NKPDSNQLIL EHAGTFFDEI QQRHGLANSI
     SSYLIKPVQR VTKYQLLLKE LLTCCEEGKG ELKDGLEVML SVPKKANDAM HVSMLEGFDE
     NLDVQGELIL QDAFQVWDPK SLIRKGRERH LFLFEISLVF SKEIKDSSGH TKYVYKNKLL
     TSELGVTEHV EGDPCKFALW SGRTPSSDNK TVLKASNIET KQEWIKNIRE VIQERIIHLK
     GALKEPIQLP KTPAKLRNNS KRDGVEDGDS QGDGSSQPDT ISIASRTSQN TVESDKLSGG
     CELTVVLQDF SAAHSSELSI QVGQTVELLE RPSERPGWCL VRTTERSPPQ EGLVPSSTLC
     ISHSRSSVEM DCFFPLVKDS YSHSSGENGG KSESVANLQS QPSLNSIHSS PGPKRSTNTL
     KKWLTSPVRR LNSGKADGNI KKQKKVRDGR KSFDLGSPKP GDETTPQGDS ADEKSKKGWG
     EDEPDEESHT PLPPPMKIFD NDPTQDEMSS LLAARQAPTD VPTAADLVSA IEKLVKSKLT
     LEGGSYRGSL KDPTVCLNEG MAPPTPPRNL EEEQKAKALR GRMFVLNELV QTEKDYVKDL
     GIVVEGFMKR IEEKGVPEDM RGKEKIVFGN IHQIYDWHKD FFLAELEKCI QEQDRLAQLF
     IKHERKLHIY VWYCQNKPRS EYIVAEYDAY FEEVKQEINQ RLTLSDFLIK PIQRITKYQL
     LLKDFLRYSE KAGLECSDIE KAVELMCLVP KRCNDMMNLG RLQGFEGTLT AQGKLLQQDT
     FYVIELDAGM QSRTKERRVF LFEQIVIFSE LLRKGSLTPG YMFKRSIKMN YLVLEEDVDD
     DPCKFALMNR ETSERVILQA ANSDIQQAWV QDINQVLETQ RDFLNALQSP IEYQRKERST
     AVIRSQPPRV PQASPRPYSS VPVGSEKPPK GSSYNPPLPP LKISTSNGSP GFDYHQPGDK
     FDASKQNDLG GCNGTSTMAV IKDYYALKEN EICVSQGEVV QVLAVNQQNM CLVYQPASDH
     SPAAEGWVPG SILAPLTKAT APAESSDESI KKSCSWHTLR MRKRADVENT GKNEATGPRK
     PKDILGNKAS VKETNSSEES ECDDLDPNTS MEILNPNFIQ EVAPEFLVPL VDVTCLLGDT
     VLLQCKACGR PKPTITWKGP DQNILDTDNS SATYTISSCD SGESTLKICN LMPQDSGIYT
     CIATNDHGTA STSATVKVQG VPAAPNRPIA QERSCTSVIL RWLPPASTGN CTISGYTVEY
     REEGSQVWQQ SVASTLDTYL VIEDLSPGCP YQFRVSASNP WGISLPSEPS EFVHLPEYDA
     AADGATISWK ENFDSAYTEL NEIGRGRFSI VKKCIHKATR KDVAVKFVSK KMKKKEQAAH
     EAALLQHLQH PQYVTLHDTY ESPTSYILIL ELMDDGRLLD YLMNHDELME EKVAFYIRDI
     MEALQYLHNC RVAHLDIKPE NLLIDLRIPV PRVKLIDLED AVQISGHFHI HHLLGNPEFA
     APEVIQGIPV SLGTDIWSIG VLTYVMLSGV SPFLDESKEE TCINVCRVDF SFPHEYFCGV
     SNAARDFINV ILQEDFRRRP TAATCLQHPW LQPHNGSYSK IPLDTSRLAC FIERRKHQND
     VRPIPNVKSY IVNRVNQGT
//
